Unicycive Therapeutics, Inc. - Common Stock (UNCY)
0.6090
-0.0161 (-2.58%)
Unicycive Therapeutics Inc is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in the areas of kidney diseases
The company is primarily engaged in creating novel drug candidates that enhance the management of renal conditions, aiming to improve patient outcomes through targeted treatments. By leveraging its expertise in drug development and its commitment to scientific research, Unicycive Therapeutics seeks to bring forth new solutions that can significantly impact the lives of individuals suffering from various kidney-related disorders.
Shares of Limbach Holdings, Inc. (NASDAQLMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Shares of 3M Company (NYSEMMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.
Shares of Coherus BioSciences, Inc. (NASDAQCHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1.5% on Friday. The Dow traded up 0.93% to 34,439.75 while the NASDAQ rose 1.54% to 13,800.92. The S&P 500, also rose, gaining, 1.32% to 4,454.48.
Gainers Addentax Group Corp. (NASDAQATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.62% to 34,333.42 while the NASDAQ rose 1.37% to 13,777.52. The S&P 500, also rose, gaining, 1.04% to 4,441.95.
